title: Neuroblastoma: paradigm for precision medicine.
abstract: Neuroblastoma (NB) is the third most common pediatric cancer. Although NB accounts for 7% of pediatric malignancies, it is responsible for more than 10% of childhood cancer-related mortality. Prognosis and treatment are determined by clinical and biological risk factors. Estimated 5-year survival rates for patients with non-high-risk and high-risk NB are more than 90% and less than 50%, respectively. Recent clinical trials have continued to reduce therapy for patients with non-high-risk NB, including the most favorable subsets who are often followed with observation approaches. In contrast, high-risk patients are treated aggressively with chemotherapy, radiation, surgery, and myeloablative and immunotherapies.
authors.affiliation: Division of Hematology-Oncology, Hospital for Sick Children, University of Toronto, 555 University Ave, Toronto, ON M5G1X8, Canada.
authors.forename: Meredith S
authors.initials: MS
authors.lastname: Irwin
authors.affiliation: Division of Hematology-Oncology, Seattle Children's Hospital, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, 4800 Sandpoint Way NE, Seattle, WA 98105, USA. Electronic address: julie.park@seattlechildrens.org.
authors.forename: Julie R
authors.initials: JR
authors.lastname: Park
mesh_terms: D020022:Genetic Predisposition to Disease; D006801:Humans; D009154:Mutation; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors; D015996:Survival Rate
keywords: ALK (anaplastic lymphoma kinase); Immunotherapy; MYCN; Myeloablative therapy (MAT); Neuroblastoma; Phox2B; Risk stratification; Segmental chromosome aberrations (SCA)